{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T05:08:37Z","timestamp":1733634517724,"version":"3.30.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T00:00:00Z","timestamp":1729900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10637-024-01480-w","type":"journal-article","created":{"date-parts":[[2024,10,26]],"date-time":"2024-10-26T11:01:53Z","timestamp":1729940513000},"page":"655-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A phase II study of ME2136 (Asenapine Maleate) plus standard antiemetic therapy for patients, including diabetic patients, receiving cisplatin-based chemotherapy"],"prefix":"10.1007","volume":"42","author":[{"given":"Satoshi","family":"Hamauchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiro","family":"Fushiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuhiro","family":"Kado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Onozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Hirashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keita","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,26]]},"reference":[{"issue":"1","key":"1480_CR1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","volume":"15","author":"PJ Hesketh","year":"1997","unstructured":"Hesketh PJ, Kris MG, Grunberg SM et al (1997) Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 15(1):103\u2013109","journal-title":"J Clin Oncol"},{"issue":"2","key":"1480_CR2","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","volume":"375","author":"RM Navari","year":"2016","unstructured":"Navari RM, Qin R, Ruddy KJ et al (2016) Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 375(2):134\u2013142","journal-title":"N Engl J Med"},{"issue":"2","key":"1480_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S1470-2045(19)30678-3","volume":"21","author":"H Hashimoto","year":"2020","unstructured":"Hashimoto H, Abe M, Tokuyama O et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(2):242\u2013249","journal-title":"Lancet Oncol"},{"key":"1480_CR4","unstructured":"(2023) NCCN clinical practice guidelines in oncology version 1. Antiemesis.\u00a0High emetic risk parenteral anticancer agents - acute and delayed emesis prevention. National Comprehensive Cancer Network"},{"issue":"8","key":"1480_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jamapsychiatry.2018.1088","volume":"75","author":"GE Nicol","year":"2018","unstructured":"Nicol GE, Yingling MD, Flavin KS et al (2018) Metabolic effects of antipsychotics on adiposity and insulin sensitivity in youths: a randomized clinical trial. JAMA Psychiat 75(8):788\u2013796","journal-title":"JAMA Psychiat"},{"issue":"11","key":"1480_CR6","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1592\/phco.21.17.1448.34421","volume":"21","author":"HL Seaburg","year":"2001","unstructured":"Seaburg HL, McLendon BM, Doraiswamy PM (2001) Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. Pharmacotherapy 21(11):1448\u20131454","journal-title":"Pharmacotherapy"},{"issue":"7","key":"1480_CR7","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1592\/phco.22.11.841.33629","volume":"22","author":"EA Koller","year":"2002","unstructured":"Koller EA, Doraiswamy PM (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22(7):841\u2013852","journal-title":"Pharmacotherapy"},{"issue":"5","key":"1480_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","volume":"27","author":"JS Silvestre","year":"2005","unstructured":"Silvestre JS, Prous J (2005) Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol 27(5):289\u2013304","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"2","key":"1480_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/MPA.0b013e3182592c96","volume":"42","author":"G Aggarwal","year":"2013","unstructured":"Aggarwal G, Kamada P, Chari ST (2013) Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 42(2):198\u2013201","journal-title":"Pancreas"},{"issue":"1","key":"1480_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/0269881107082944","volume":"23","author":"M Shahid","year":"2009","unstructured":"Shahid M, Walker GB, Zorn SH et al (2009) Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 23(1):65\u201373","journal-title":"J Psychopharmacol"},{"key":"1480_CR11","unstructured":"(2020)\u00a0 Meiji Seika Pharma Co., Ltd. SYCREST\u00ae Sublingual Tablets Drug Product Interview Form Ver.6. pp 28\u201329"},{"issue":"14","key":"1480_CR12","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s00213-016-4295-9","volume":"233","author":"T Kinoshita","year":"2016","unstructured":"Kinoshita T, Bai YM, Kim JH et al (2016) Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology 233(14):2663\u20132674","journal-title":"Psychopharmacology"},{"key":"1480_CR13","unstructured":"Treatment guide for diabetes 2020\u20132021: Japan diabetes society, pp 24\u201333"},{"key":"1480_CR14","unstructured":"(2020) Zyprexa\u00ae Tablets Drug Product Interview Form Ver.24, pp 75\u201376"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-024-01480-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-024-01480-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T09:11:56Z","timestamp":1733562716000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-024-01480-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,26]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1480"],"URL":"https:\/\/doi.org\/10.1007\/s10637-024-01480-w","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2024,10,26]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline. It was reviewed and approved by the Certified Review Board of the Shizuoka Cancer Center(30 October 2020 \/ 2020\u201317-2020\u20131-6).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All enrolled patients provided their informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Satoshi Hamauchi reports lecture fees from Ono Pharmaceutical Co., Ltd.\u00a0Tomoya Yokota reports advisor to Merck Biopharma, MSD, Rakuten Medical, and Astellas Pharma and lecture fees from Merck Biopharma, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb, AstraZeneca, Chugai Pharmaceutical Co., Ltd., MSD, Eli Lilly Japan, and Eisai. Takahiro Tsushima reports lecture fees from Taiho Pharmaceutical Co., Ltd., Ono pharmaceutical Co., Ltd., Bristol Meyers Squibb Co., and MSD.\u00a0Kunihiro Fushiki reports lecture fees from Ono pharmaceutical Co., Ltd., Bristol-Meyers Squibb Co., and MSD. Tateaki Naito reports grants from Kracie Holdings and lecture fees from Ono Pharmaceutical Co., Ltd. outside the submitted work. Akira Ono reports lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., BMS, and Indica labs; research grants to institution from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., and Janssen Pharmaceutical K.K.\u00a0Yusuke Onozawa reports lecture fees from Novartis.\u00a0Haruyasu Murakami reports grants and lecture fees from AstraZeneca K.K., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo, and Taiho Pharmaceutical Co., Ltd., grants from AbbVie, IQvia, and Bayer, lecture fees from Takeda, Amgen, Bristol-Myers Squibb, MSD, Pfizer, Novartis, Eli Lilly Japan, Eisai, and Nihonkayaku, advisory to Chugai Pharmaceutical Co., Ltd., GAIA BioMedicine, Daiichi Sankyo, Takeda, and Kyowa Kirin.\u00a0Kentaro Yamazaki reports research funding from Esai., Pfizer., and Ono Pharmaceutical Co., Ltd., and lecture fees from Chugai Pharmaceutical Co., Ltd., Takeda, Eli Lilly Japan, Taiho Pharmaceutical Co., Ltd., Merck biopharma, Yakult, Ono pharmaceutical Co., Ltd., Bristol-Myers Squibb.\u00a0Toshiaki Takahashi reports grants from AstraZeneca K.K., Chugai Pharma Co., Ltd., Eli Lilly Japan, Ono Pharmaceutical Co., Ltd., MSD, Pfizer, AMGEN, Boehringer Ingelheim, Merck Biopharma, personal fees from AstraZeneca K.K., Chugai Pharma Co., Ltd., Eli Lilly Japan, Ono Pharmaceutica Co., Ltd., MSD, Pfizer, Boehringer Ingelheim, Roche Diagnostics, Takeda, and Yakult, outside the submitted work.\u00a0Yasuyuki Hirashima reports grants from AstraZeneca K.K., Ezai, Merck Biopharma, and MSD, lecture fees from AstraZeneca K.K., Chugai Pharma Co., Ltd., and Takeda outside the submitted work.\u00a0Keita Mori reports lecture fees from Ono Pharmaceutical Co., Ltd. outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}